Carbohydrate antigen 19-9 is a valuable prognostic factor in colorectal cancer patients with normal levels of carcinoembryonic antigen and may help predict lung metastasis

International Journal of Colorectal Disease

Volumn 27, Issue 10, 2012, Pages 1333-1338

  Lin, Pei Ching ^a   Lin, Jen Kou ^b   Lin, Chun Chi ^b   Wang, Huann Sheng ^b   Yang, Shung Haur ^b   Jiang, Jeng Kai ^b   Lan, Yuan Tzu ^b   Lin, Tzu Chen ^b   Li, Anna Fen Yau ^b   Chen, Wei Shone ^b   Chang, Shih Ching ^b  

^a TAIPEI CITY HOSPITAL   (Taiwan)

^b NATIONAL YANG MING UNIVERSITY   (Taiwan)

Author keywords

CA19 9; CEA; Colorectal cancer; Prognosis

Indexed keywords

CA 19-9 ANTIGEN; CARCINOEMBRYONIC ANTIGEN;

ADULT; AGED; ARTICLE; CANCER INCIDENCE; CANCER PROGNOSIS; CANCER STAGING; COLORECTAL CANCER; COLORECTAL SURGERY; CONTROLLED STUDY; DISEASE FREE SURVIVAL; FEMALE; FOLLOW UP; GENERAL HOSPITAL; HUMAN; LOG RANK TEST; LUNG METASTASIS; MAJOR CLINICAL STUDY; MALE; MULTIVARIATE ANALYSIS; POSTOPERATIVE PERIOD; PREDICTION; PREOPERATIVE EVALUATION; PRIORITY JOURNAL; PROPORTIONAL HAZARDS MODEL; RETROSPECTIVE STUDY; TAIWAN;

AGED; CA-19-9 ANTIGEN; CARCINOEMBRYONIC ANTIGEN; COLORECTAL NEOPLASMS; DISEASE-FREE SURVIVAL; HUMANS; LUNG NEOPLASMS; MULTIVARIATE ANALYSIS; NEOPLASM STAGING; PROGNOSIS; TUMOR MARKERS, BIOLOGICAL;

EID: 84866935334     PISSN: 01791958     EISSN: 14321262     Source Type: Journal    
DOI: 10.1007/s00384-012-1447-1     Document Type: Article

References (22)

1. The Department of Health, the Executive Yuan, Taiwan (2007) Cancer registry annual report (December 2007). The Department of Health, the Executive Yuan, Taiwan
2. Compton CC, Fielding LP, Burgart LJ, Conley B, Cooper HS, Hamilton SR, Hammond ME, Henson DE, Hutter RV, Nagle RB, Nielsen ML, Sargent DJ, Taylor CR, Welton M, Willett C (2000) Prognostic factors in colorectal cancer. College of American Pathologists Consensus Statement 1999. Arch Pathol Lab Med 124:979-994
3. Desch CE, Benson AB 3rd, Somerfield MR, Flynn PJ, Krause C, Loprinzi CL, Minsky BD, Pfister DG, Virgo KS, Petrelli NJ (2005) Colorectal cancer surveillance: 2005 update of an American Society of Clinical Oncology practice guideline. J Clin Oncol 23:8512-8519
4. Compton C, Fenoglio-Preiser CM, Pettigrew N, Fielding LP (2000) American Joint Committee on Cancer Prognostic Factors Consensus Conference: Colorectal Working Group. Cancer 88:1739-1757
5. Bast RC Jr, Ravdin P, Hayes DF, Bates S, Fritsche H Jr, Jessup JM, Kemeny N, Locker GY, Mennel RG, Somerfield MR (2001) 2000 update of recommendations for the use of tumor markers in breast and colorectal cancer: clinical practice guidelines of the American Society of Clinical Oncology. J Clin Oncol 19:1865-1878
6. Duffy MJ, van Dalen A, Haglund C, Hansson L, Klapdor R, Lamerz R, Nilsson O, Sturgeon C, Topolcan O (2003) Clinical utility of biochemical markers in colorectal cancer: European Group on Tumour Markers (EGTM) guidelines. Eur J Cancer 39:718-727
7. Locker GY, Hamilton S, Harris J, Jessup JM, Kemeny N, Macdonald JS, Somerfield MR, Hayes DF, Bast RC Jr (2006) ASCO 2006 update of recommendations for the use of tumor markers in gastrointestinal cancer. J Clin Oncol 24:5313-5327
8. Duffy MJ, van Dalen A, Haglund C, Hansson L, Holinski-Feder E, Klapdor R, Lamerz R, Peltomaki P, Sturgeon C, Topolcan O (2007) Tumour markers in colorectal cancer: European Group on Tumour Markers (EGTM) guidelines for clinical use. Eur J Cancer 43:1348-1360
9. Lin JK, Lin CC, Yang SH,Wang HS, Jiang JK, Lan YT, Lin TC, Li AF, Chen WS, Chang SC (2011) Early postoperative CEA level is a better prognostic indicator than is preoperative CEA level in predicting prognosis of patients with curable colorectal cancer. Int J Colorectal Dis 26:1135-1141
10. Nakagoe T, Sawai T, Tsuji T, Jibiki MA, Nanashima A, Yamaguchi H, Yasutake T, Ayabe H, Arisawa K (2003) Preoperative serum level of CA19-9 predicts recurrence after curative surgery in nodenegative colorectal cancer patients. Hepatogastroenterology 50:696-699
11. Chen CC, Yang SH, Lin JK, Lin TC, Chen WS, Jiang JK, Wang HS, Chang SC (2005) Is it reasonable to add preoperative serum level of CEA and CA19-9 to staging for colorectal cancer? J Surg Res 124:169-174
12. Nozoe T, Rikimaru T, Mori E, Okuyama T, Takahashi I (2006) Increase in both CEA and CA19-9 in sera is an independent prognostic indicator in colorectal carcinoma. J Surg Oncol 94:132-137
13. Del Villano BC, Brennan S, Brock P, Bucher C, Liu V, McClure M, Rake B, Space S, Westrick B, Schoemaker H, Zurawski VR Jr (1983) Radioimmunometric assay for a monoclonal antibodydefined tumor marker, CA 19-9. Clin Chem 29:549-552
14. Greene FLPD, Fleming ID, Fritz AG, Balch CM, Haller DG, Morrow M (2002) AJCC cancer staging manual, 6th edn. Springer, Chicago
15. Magnani JL, Nilsson B, Brockhaus M, Zopf D, Steplewski Z, Koprowski H, Ginsburg V (1982) A monoclonal antibodydefined antigen associated with gastrointestinal cancer is a ganglioside containing sialylated lacto-N-fucopentaose II. J Biol Chem 257:14365-14369
16. Nakayama T, Watanabe M, Teramoto T, Kitajima M (1997) CA19-9 as a predictor of recurrence in patients with colorectal cancer. J Surg Oncol 66:238-243
17. Berg EL, Magnani J, Warnock RA, Robinson MK, Butcher EC (1992) Comparison of L-selectin and E-selectin ligand specificities: the L-selectin can bind the E-selectin ligands sialyl Le(x) and sialyl Le(a). Biochem Biophys Res Commun 184:1048-1055
18. Nakayama T, Watanabe M, Teramoto T, Kitajima M (1997) Slope analysis of CA19-9 and CEA for predicting recurrence in colorectal cancer patients. Anticancer Res 17:1379-1382
19. Redson M (2001) Carcinogenesis in the GI tract: from morphology to genetics and back again. Mod Pathol 230:309-318
20. Distler P, Holt PR (1997) Are right and left-sided colon neoplasms distinct tumors? Dig Dis 15:302-311
21. Thibodeau SN, Bren G, Schaid D (1993) Microsatellite instability in cancer of the proximal colon. Science 260:816-819
22. Engstrom PF, Arnoletti JP, Benson AB 3rd, Chen YJ, Choti MA, Cooper HS et al (2009) NCCN Clinical Practice Guidelines in Oncology: colon cancer. Natl Compr Cancer Netw 7:778-831